Figures Guide:
Figure 1 . Duration of treatment with a combination of
cabozantinib, topotecan and cyclophosphamide in patients with relapsed
or refractory Ewing sarcoma and osteosarcoma (n=12).
Figure 2. Best percent change in tumor size from baseline for
patients with relapsed or refractory Ewing sarcoma and osteosarcoma with
measurable disease (n=5)
Figure 3. Spider plots demonstrating ctDNA levels throughout
study duration for A) patients with osteosarcoma and B) patients with
Ewing sarcoma